Compounded medications specifically carry the additional caveat that they're not FDA-reviewed for safety, effectiveness, or quality - and dosing errors with multidose vials have been documented across the compounded GLP-1 category
has been a supported speaker or consultant for AstraZeneca, Boehringer Ingelheim, Kallyope, Merck, Novo Nordisk and Pfizer, as well as receives grant support for preclinical studies from Amgen, Zealand Pharma and Eli Lilly
The Incretin Effect (Pancreatic Response) GLP-1 travels to the pancreas, where it binds to specific receptors on beta cells
Semaglutide medications work by activating the GLP-1 receptor alone, while tirzepatide medications activate both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, creating what is commonly described as a dual incretin mechanism